Week 4- HEENT Flashcards
(131 cards)
Describe the eye overview
- Anterior section
- Posterior section
- Ciliary body
- The eye is separated into two segments by the lens (anterior and posterior sections)
- Anterior section (comprised of anterior and posterior chambers) filled with aqueous humor (AH)
- Posterior section filled with vitreous humor
- Ciliary body: ring-like structure that surrounds and supports lens
- Secretes AH
Eye Overview
- What does the aqueous humor provide?
- Where does aqueous humor drain/exit?
- AH provides oxygen and nutrients
- 80% drains through trabecular meshwork in the anterior chamber
- 20% exits anterior chamber through iris root and spaces in ciliary muscle – uveoscleral outflow
Describe glaucoma.
- Glaucoma
- Progressive optic neuropathy cause by elevated intraocular pressure (IOP) > 21 mmHg leading to optic nerve damage
- Normal IOP 10-21 mm Hg
- Progressive optic neuropathy cause by elevated intraocular pressure (IOP) > 21 mmHg leading to optic nerve damage
Differentiate between the two different types of glaucoma.
- Open-angle
- Angle-closure
- Open-angle glaucoma
- Silent disease
- Obstruction in aqueous humor outflow by obstruction of the trabecular meshwork
- Peripheral vision loss
- Angle-closure glaucoma
- Medical emergency
- Obstruction of anterior chamber angle resulting in intermittent or acutely elevate IOP with optic nerve damage
What are the treatment goals of glaucoma?
- Prevent further loss of vision
- Minimize adverse effects of therapy and impact on vision, general health, and quality of life
- Maintain IOP at or below a pressure which further optic nerve damage could occur
- Goal at least 25% lower than the patient’s baseline IOP
What is the role of the PCP in glaucoma management?
- Role of primary care provider:
- Refer to ophthalmologist for suspicion of glaucoma
- Be aware of medications that are prescribed, drug interactions, and adverse effects from these medications
Discuss the 4 differenet non-pharmacological treatment options for glaucoma.
- Laser trabeculoplasty
- Laser energy aimed at trabecular meshwork
- Trabeculectomy
- Surgical removal of a portion of the trabecular meshwork
- Cyclodestructive surgery
- Trans-scleral laser reduces rate of aqueous humor production
- Aqueous shunts
- Drainage device that redirects the outflow of aqueous humor through a small tube into an outlet chamber placed underneath the conjunctiva
Glaucoma: Prostaglandin analogs
-Mechanism of action
- Mechanism of action (MOA): reduce IOP by binding to the FP receptor (subtype of prostaglandin receptor) to increase the outflow of aqueous humor through uveoscleral outflow
Glaucoma: Prostaglandin analogs
-Agents
- Latanoprost (Xaltan®) 0.005% solution
- Bimatoprost (Lumigan®) 0.01% and 0.03% solution
- Travoprost (Travatan Z®) 0.004% solution
- Tafluprost (Zioptan®) 0.0015% solution
Glaucoma: Prostaglandin analogs
-Adverse effects
- Adverse effects:
- Ocular hyperemia (eye redness)
- Increased number and length of eyelashes
- Changes in eye color (may be permanent)
- Rare: uveitis or cystoid macular edema
Glaucoma: Prostaglandin analogs
-Warning/Precautions
- Permanent pigmentation of the iris and/or eyelids, and increase number/length of eyelashes
Glaucoma: Alpha-adrenergic
-Agents
- Agents:
- Brimonidine (Alphagan P® ) 0.15% 0.15%, 0.2% solution
- Brimonidine (Lumify®[OTC]) 0.025% solution
- Apraclonidine (Iopidine®) 0.5%, 1% solution
Glaucoma: Alpha-adrenergic
-MOA
- MOA: decrease intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow
Glaucoma: Alpha-adrenergic
-Adverse effects
- Adverse effects:
- Sensation of foreign body in eye
- Ocular pain
- Drowsiness
- Dry eyes
Glaucoma: Alpha-adrenergic
-Contraindications/Warnings & Precautions
- Contraindications:
- Concomitant MAO inhibitor therapy
- Warnings/Precautions:
- <6 years old (risk of respiratory depression)
- Caution in patients with CVD, depression, orthostatic hypotension
Glaucoma: Beta Blockers
-Agents
- Timolol (Timoptic®, Betimol®) 0.25%, 0.5% solution
- Betaxolol (Betoptic-S®)0.5% solution (generic) 0.25% suspension (brand)
- Levobunol (Betagan®) 0.25%, 0.5% solution
- Metipranolol (OptiPranolol®) 0.3% solution
Glaucoma: Beta Blockers
-MOA
- MOA: interfering with the production of aqueous humor induced by cyclic adenosine monophosphate (cAMP)
Glaucoma: Beta Blockers
-Adverse effects
- Adverse effects:
- Local: eye irritation/stinging
- Systemic: headaches, dizziness, bradycardia, masking hypoglycemic
Glaucoma: Beta Blockers
- Contraindications
- Warnings/Precautions
- Contraindications:
- Bronchial asthma, severe COPD
- Sinus bradycardia, 2nd or 3rd degree AV block, heart failure, cardiogenic shock
- Warnings/Precautions:
- Caution in patients with cardiovascular disease, diabetes, heart failure, myasthenia gravis, respiratory diseases, and thyroid disease
Glaucoma: Carbonic anhydrase inhibitors
-Agents
- Agents:
- Brinzolamide (Azopt®) 1% suspension
- Dorzolamide (Trusopt®) 2% solution
Glaucoma: Carbonic anhydrase inhibitors
-MOA
- MOA: slows the formation of bicarbonate ions, which reduces sodium and fluid transport and leads to decreased production of aqueous humor
Glaucoma: Carbonic anhydrase inhibitors
-Adverse Effects
- Adverse effects:
- Dysgeusia (bitter taste) ~25%
- Eye discomfort/burning sensation
- Blurred vision
- Eyelid irritation/eye redness
- Photophobia/headache
Glaucoma: Carbonic anhydrase inhibitors
-Warnings/Precautions
- Warnings/Precautions:
- Sulfonamide – caution with sulfa allergies, but most patients can tolerate
Glaucoma: Miotics, cholinesterase inhibitors
-Agents
- Carbachol (Carboptioc®) 1.5%, 3% solution
- Pilocarpine (Isopto Carpine®, Diocarpine®) 0.25-10% solution